Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Breakthrough in Schizophrenia Treatment
FDA Approves groundbreaking drug for schizophrenia treatment
On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way. Cobenfy (xanomeline and trospium chloride) capsules are the first antipsychotic drug approved to target cholinergic receptors. All other treatments available for schizophrenia target the dopamine receptors.
First Novel Schizophrenia Treatment in Decades Gains FDA Approval
The first new kind of treatment for schizophrenia patients in decades is arriving. The U.S. Food and Drug Administration approved the drug on Thursday, greenlighting the first of a new class of treatments that could help stabilize patients’ symptoms without the uncomfortable side effects that accompany existing antipsychotics.
FDA approves first new medication to treat schizophrenia in more than 30 years
People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental illness in more than 30 years.
FDA approves 1st new drug for schizophrenia in more than 30 years
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years.
Schizophrenia: US approves first new treatment in decades
The US Food and Drug Administration (FDA) has approved xanomeline and trospium chloride capsules (Cobenfy) for the treatment of schizophrenia in adults. The drug is the first antipsychotic treatment with a novel mode of action to be approved for the condition in more than 50 years.
FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with schizophrenia.
The 'game-changing' treatment for schizophrenia
US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects
Cobenfy: The First New Schizophrenia Drug in Decades
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other antipsychotics.
Experts hail new schizophrenia drug Cobenfy as a game-changer, the ‘first of its kind’
Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer side effects British scientists have hailed the US approval of a new drug for schizophrenia,
Breakthrough in Schizophrenia Treatment: FDA Approves Cobenfy
New drug offers hope for patients with Schizophrenia that has long eluded effective treatment. Read on to know more.
ScienceAlert
16m
First New Schizophrenia Treatment in Decades a Much-Needed Alternative
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...
McKnight's Long-Term Care News
2h
Schizophrenia treatment offers alternative with fewer side effects
The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major ...
3d
Bristol Myers wins US FDA approval for new type of schizophrenia drug
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
New Atlas
4d
Synapse-restoring pill set for human trials as novel schizophrenia treatment
Spinogenix, the company behind the once-a-day pill that restored lost nerve cell connections in people with amyotrophic ...
Medical News Today
4d
Is lithium an effective treatment for schizophrenia?
Doctors sometimes use lithium to treat schizophrenia. However, it is not a primary treatment method and evidence of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Cobenfy
KarXT
Bristol Myers Squibb
Food and Drug Administration
Feedback